)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Protagonist Therapeutics
Protagonist Therapeutics (PTGX) investor relations material
Protagonist Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Growth and value creation outlook
Next 12–24 months expected to bring significant growth, driven by two potential blockbuster approvals, multiple clinical readouts, new discovery programs, and a strong cash position.
Two key partnered assets, Icotide (with J&J) and Rusfertide (with Takeda), are approaching commercialization.
Pipeline expansion includes new fully owned assets and discovery programs targeting high-priority areas like IL-4 and amylin.
Financial strength supports both internal R&D and potential shareholder returns.
Key assets and clinical progress
Icotide is positioned as the first oral IL-23 pathway blocker, targeting psoriasis and other IL-23-mediated diseases, with a potential $10B+ market opportunity.
Phase III data for Icotide show high efficacy and placebo-like safety, supporting NDA filing and anticipated commercial launch in psoriasis this year.
Rusfertide, a synthetic hepcidin mimetic for PV, demonstrated practice-changing results in Phase III and is expected to launch in the second half of the year.
Both assets have comprehensive clinical data packages and expedited regulatory pathways.
Pipeline innovation and new announcements
PN-881, a best-in-class oral IL-17 antagonist, is in Phase I with Phase II in psoriasis planned by year-end.
PN-8047, an oral hepcidin mimetic small molecule, complements Rusfertide and is expected to enter Phase I by year-end.
Obesity portfolio expanded with PN-477 (oral triple agonist), PN-458 (dual GLP-1/GIP agonist), and a high-priority amylin program, all with oral and SubQ options.
IL-4 added as a new high-priority discovery target for I&I indications.
How will rusfertide opt-out impact financials?
Oral hepcidin (8047) small molecule rationale
Capital allocation strategy for future cash flow
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Protagonist Therapeutics earnings date
Q4 202520 Feb, 2026
Protagonist Therapeutics
Next Protagonist Therapeutics earnings date
Q4 202520 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative peptide-based therapeutic drugs aimed at addressing unmet medical needs. The company's focus encompasses a broad range of diseases, with a particular emphasis on rare and prevalent conditions where existing treatments are limited or inadequate. Protagonist Therapeutics' technology platform has produced a pipeline of promising drug candidates, including peptide-based drugs for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage